【摘要】：目的:研究蒙藥達(dá)日布-8對(duì)動(dòng)脈粥樣硬化(AS)模型兔內(nèi)皮祖細(xì)胞(EPCs)數(shù)量的調(diào)節(jié)作用。方法:將60只雄性新西蘭兔隨機(jī)分成6組:空白對(duì)照(A)組、模型對(duì)照(B)組、辛伐他汀(C)組、達(dá)日布-8低劑量(D)組、達(dá)日布-8中劑量(E)組、達(dá)日布-8高劑量(F)組,每組10只,每天給相應(yīng)飼料并灌胃相應(yīng)藥物,飼養(yǎng)12周。分別于第0、4、8、12周,禁食12h后,耳緣靜脈取血,經(jīng)密度梯度離心法分離細(xì)胞、培養(yǎng)、鑒定。結(jié)果:B組內(nèi)膜斑塊形成明顯,鏡下可見大量泡沫細(xì)胞、脂質(zhì)沉積,斑塊向血管腔內(nèi)突入,中膜平滑肌細(xì)胞呈不規(guī)則增生,證明模型有效。經(jīng)Dil-Ac-LDL和FITC-UEA-I雙染色后,第12周,與A組比較,B組雙陽性細(xì)胞數(shù)量減少(P0.01),與B組比較,F組雙陽性細(xì)胞增多(P0.01)。經(jīng)熒光雙抗CD34、VEGFR-2聯(lián)合EPCs表型雙染色后,第8周,兔外周血EPCs數(shù)量不同程度的發(fā)生變化,但與B組比較,各給藥組差異并不顯著。灌胃至第12周時(shí),與B組比較,C、E、F組EPCs數(shù)量均明顯增多(P0.01)。結(jié)論:大劑量蒙藥達(dá)日布-8可以通過動(dòng)員體內(nèi)EPCs達(dá)到防治AS的作用。
[Abstract]:Aim: to study the effect of Mongolian drug Dazibu-8 on the (EPCs) quantity of endothelial progenitor cells in atherosclerotic (AS) model rabbits. Methods: sixty male New Zealand rabbits were randomly divided into 6 groups: blank control group (A), model control group (B), simvastatin (C) group, Dazibu-8 low dose (D) group, Dazibu-8 medium dose (E) group, Dazibu-8 high dose (F) group (10 rats in each group). The rats were fed with feed and medicine daily for 12 weeks. After fasting for 12 hours, the blood was taken from the vein of the auricular margin. The cells were isolated by density gradient centrifugation, cultured and identified. Results in group B, a large number of foam cells and lipid deposits were observed in the intimal plaques. The plaque protruded into the vascular lumen, and the medial smooth muscle cells showed irregular proliferation, which proved that the model was effective. At the 12th week after Dil-Ac-LDL and FITC-UEA-I double staining, the number of double positive cells in group B was lower than that in group A (P0.01), and the number of double positive cells in group F was more than that in group B (P0.01). After fluorescence double antibody CD34,VEGFR-2 combined with EPCs phenotype double staining, the number of EPCs in peripheral blood of rabbits changed in different degrees at the 8th week, but there was no significant difference between each administration group and group B. Compared with group B, the number of EPCs in group C (P 0.01) was significantly higher than that in group B (P < 0.01). Conclusion: large dose of Mongolian drug Dazibu-8 can prevent and cure AS by mobilizing in vivo EPCs.
【作者單位】： 內(nèi)蒙古醫(yī)科大學(xué);內(nèi)蒙古阿拉善盟蒙醫(yī)醫(yī)院;內(nèi)蒙古呼倫貝爾市蒙醫(yī)醫(yī)院;
【基金】：國(guó)家自然科學(xué)基金項(xiàng)目主任基金項(xiàng)目(No.81341114)~~
【分類號(hào)】：R29

【相似文獻(xiàn)】

相關(guān)期刊論文 前1條

1 鄭萬華;蒙藥"達(dá)日布-罕達(dá)"應(yīng)用前景分析[J];中國(guó)民族醫(yī)藥雜志;2004年04期

，

本文編號(hào)：2215650